Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of “Hold” from Analysts

Invivyd, Inc. (NASDAQ:IVVD) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several research firms recently issued reports on IVVD. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th.

Invivyd Price Performance

Shares of IVVD opened at $0.54 on Monday. Invivyd has a 52-week low of $0.48 and a 52-week high of $3.07. The company has a market capitalization of $157.62 million, a PE ratio of -1.73 and a beta of 0.71. The stock has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $1.36.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The company had revenue of $13.74 million for the quarter, compared to analysts’ expectations of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. As a group, equities analysts anticipate that Invivyd will post -0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC acquired a new stake in Invivyd during the fourth quarter worth $14,349,000. Perceptive Advisors LLC purchased a new stake in Invivyd in the fourth quarter valued at $53,809,000. BVF Inc. IL acquired a new position in shares of Invivyd in the 4th quarter valued at $48,227,000. UBS Group AG lifted its stake in shares of Invivyd by 683.8% in the 4th quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock valued at $2,596,000 after purchasing an additional 916,842 shares during the last quarter. Finally, SummitTX Capital L.P. purchased a new position in shares of Invivyd during the 1st quarter worth $37,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.